Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
Exicure (Nasdaq:XCUR) plans to issue 172,058 shares of common stock to GPCR Therapeutics during August 2026 to settle a $1.0 million clinical milestone obligation under their License and Collaboration Agreement.
Rhea-AI Summary
Exicure (Nasdaq:XCUR) plans to issue 172,058 shares of common stock to GPCR Therapeutics during August 2026 to settle a $1.0 million clinical milestone obligation under their License and Collaboration Agreement. The payment obligation arose from completion of the Phase 2 clinical trial of Burixafor (GPC-100) and formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026.
The shares are expected to be issued at a deemed value of $5.81 per share, based on applicable Nasdaq trading data, for an aggregate deemed value of approximately $1.0 million. Exicure submitted a Listing of Additional Shares Notification to Nasdaq on July 31, 2026 and delivered issuance instructions to its transfer agent. The issuance is expected to be completed in August 2026, subject to customary Nasdaq and transfer agent review. Exicure’s CEO said the equity settlement is intended to preserve cash and maintain financial flexibility.
Positive
- $1.0 million milestone settled via equity, preserving cash resources
- Planned issuance of 172,058 shares fixes equity consideration and valuation
- Phase 2 trial of Burixafor (GPC-100) completed with CSR submitted on Jan 16, 2026
Negative
- Issuance of 172,058 new shares adds to share count and dilutes existing holders
- Equity-settled $1.0 million milestone reflects additional non-operating cost obligation
Details
News Market Reaction – XCUR
In the Aug 3 session, XCUR declined 1.25%, reflecting a mild negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Shares to be issued
- 172,058 shares
- Settlement of clinical milestone payment
- Milestone payment
- $1.0 million
- Obligation under the License and Collaboration Agreement
- Trial phase
- Phase 2
- Burixafor clinical trial
- Clinical Study Report submission
- January 16, 2026
- Formal submission to the U.S. Food and Drug Administration
- Deemed issue value
- $5.81 per share
- Based on applicable Nasdaq trading data
- Aggregate deemed value
- $1.0 million
- Equity issuance settlement
Historical Context
-
Board expanded and committee memberships changed following a director resignation.
-
Nasdaq cited noncompliance with the minimum stockholders’ equity requirement.
-
Nasdaq issued a delinquency notice after the delayed quarterly filing.
-
Adbiotech agreed to explore combination therapies using Burixafor.
-
Cash declined and management cited insufficient liquidity for the next twelve months.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
clinical study report regulatory
phase 2 clinical trial medical
transfer agent financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a
The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026.
The shares are expected to be issued at a deemed value of
On July 31, 2026, the Company submitted a Listing of Additional Shares Notification to The Nasdaq Stock Market in connection with the equity issuance. The Company also completed and delivered the applicable treasury issuance instructions to its transfer agent, Equiniti Trust Company, LLC.
The Company expects the issuance to be completed during August 2026, subject to the completion of customary Nasdaq and transfer agent review and processing procedures. Exicure intends to provide an additional update following completion of the issuance.
“Settling this milestone payment through the issuance of common stock will allow Exicure to preserve cash and maintain financial flexibility as we continue to pursue our operational and strategic priorities,” said Jung Soo Kim, Chief Executive Officer of Exicure.
About Exicure, Inc.
Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. In January 2025, it acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases. The Company’s lead program is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the anticipated issuance of shares to GPCR Therapeutics, the expected timing and completion of the issuance, the settlement of the Company’s milestone payment obligation, and the Company’s strategic direction. Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.
Media Contact
Exicure, Inc.
pr@exicuretx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.